Ann Partridge

Learn More
PURPOSE To develop guidance to practicing oncologists about available fertility preservation methods and related issues in people treated for cancer. METHODS An expert panel and a writing committee were formed. The questions to be addressed by the guideline were determined, and a systematic review of the literature from 1987 to 2005 was performed, and(More)
PURPOSE To update guidance for health care providers about fertility preservation for adults and children with cancer. METHODS A systematic review of the literature published from March 2006 through January 2013 was completed using MEDLINE and the Cochrane Collaboration Library. An Update Panel reviewed the evidence and updated the recommendation(More)
PURPOSE Young women with breast cancer often seek advice about whether treatment will affect their fertility. We sought to gain a better understanding of women's attitudes about fertility and how these concerns affect decision making. PATIENTS AND METHODS We developed a survey about fertility issues for young women with a history of early-stage breast(More)
PURPOSE Although clinical trials have clearly demonstrated the benefits of tamoxifen in women with primary breast cancer, little is known about how this drug is actually used in the general population. We sought to estimate adherence and predictors of nonadherence in women starting tamoxifen as adjuvant breast cancer therapy. PATIENTS AND METHODS Subjects(More)
F. Cardoso1*, A. Costa2,3, L. Norton4, E. Senkus5, M. Aapro6, F. André7, C. H. Barrios8, J. Bergh9, L. Biganzoli10, K. L. Blackwell11, M. J. Cardoso12, T. Cufer13, N. El Saghir14, L. Fallowfield15, D. Fenech16, P. Francis17, K. Gelmon18, S. H. Giordano19, J. Gligorov20, A. Goldhirsch21, N. Harbeck22, N. Houssami23, C. Hudis24, B. Kaufman25, I. Krop26, S.(More)
PURPOSE Previous research evaluating adherence to tamoxifen therapy among women with early-stage breast cancer has revealed adherence estimates ranging from 25% to 96%. No previous studies have focused on adherence to adjuvant aromatase inhibitors. METHODS We used longitudinal claims data from three large commercial health programs to estimate adherence(More)
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local and regional therapies for early breast cancer, supporting less extensive surgery to the axilla and shorter durations of radiation therapy. It refined its earlier approach to the classification and management(More)
BACKGROUND Older women with breast cancer are underrepresented in clinical trials, and data on the effects of adjuvant chemotherapy in such patients are scant. We tested for the noninferiority of capecitabine as compared with standard chemotherapy in women with breast cancer who were 65 years of age or older. METHODS We randomly assigned patients with(More)
With the rise in availability and increasing use of oral anticancer agents, concerns about adherence to prescribed regimens will become an increasingly important issue in oncology. Few published studies have focused on adherence to oral antineoplastic therapy, in part because the vast majority of chemotherapy is delivered intravenously in physicians'(More)
Given the recent significant increase in the use of oral therapies in cancer management, an understanding of patients' adherence to and persistence with oral therapy is crucial. Nonadherence and early cessation may be substantial barriers to the delivery of valuable therapies, and may impair health. Potential obstacles to adherence and persistence include(More)